Morinidazole

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

吗啉硝唑表现出抗菌活性，可用于厌氧菌引起的阑尾炎、盆腔炎等细菌感染研究。

Morinidazole shows antibacterial activity and can be used in studies about bacterial infections research such as appendicitis and pelvic inflammatory disease caused by anaerobic bacteria.(In Vitro):Morinidazole shows antibacterial activity against Trichomonas vaginalis and Entamoeba histolytica with MICs of 2 and 3 μg/mL.(In Vivo):Morinidazole (20 and 25 mg/kg; p.o.) inhibits Trichomonas vaginalis and Entamoeba histolytica in vivo. In the renal failure model in SD rats, Morinidazole (50 mg/kg; i.v.) shows a higher concentration in the liver, plasma, and kidney than lung, spleen, and heart.

Morinidazole can be metabolized to N+-glucuronide of S-morinidazole [M8-1] and N+-glucuronide of R-morinidazole [M8-2] via N+-glucuronidation, and sulfate conjugate of morinidazole [M7] via sulfation.M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (Km=28.6 and 54.0 μM, respectively), M8-1 and M8-2 are the substrates for OAT3.Morinidazole shows activity against Trichomonas vaginalis and Entamoeba histolytica in vitro, with MIC values of 2 μg/mL and 3 μg/mL, respectively.

Morinidazole (20 mg/kg or 25 mg/kg; p.o.; single dose) inhibits Trichomonas vaginalis and Entamoeba histolytica in vivo in rats with EC50s of 20 mg/kg and 25 mg/kg, respectively.Morinidazole (50 mg/kg; i.v.; 0.25, 0.75, 1.5 h) shows a different concentration in tissues after intravenous injection, with a higher concentration in liver, kidney, plasma than lung, heart, and spleen in mice.Pharmacokinetic parameters of Morinidazole in control and 5/6 nephrectomized (Nx) rats.Intravenous injection; 50 mg/kg Morinidazole; Blood samples were collected from retro-orbital venous plexus before the dose (0 hours), at 5, 15, and 30 minutes, and at 1, 2, 4, 6, 8, and 12 hours after the dose. Animal Model:Renal failure model in SD rats (180-220 g)Dosage:50 mg/kg Administration:Intravenous injection; sacrificed rats at 0.25, 0.75, and 1.50 hours after dose administration Result:Increased plasma exposures slightly compared with control.

——

GPCR/G Protein

Antibacterial

——

——

——

92478-27-8

270.289

C11H18N4O4

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (369.97 mM)

Cc1ncc(n1CC(O)CN1CCOCC1)[N+]([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years